T细胞核医学分子成像策略在CAR-T免疫治疗中的应用

Application of T cell nuclear imaging strategy in chimeric antigen receptor T-cell immunotherapy

嵌合抗原受体T细胞(CAR-T)疗法是近年来兴起的一种肿瘤免疫治疗策略,尤以在弥漫性大B细胞淋巴瘤和急性淋巴细胞白血病中疗效最佳,但受限于实体瘤复杂的肿瘤微环境,CAR-T疗法在实体瘤治疗中的应用仍处于研究阶段。分子影像能够实时、深度、有效地对T细胞的体内状态进行示踪,对考察CAR-T在体内的生物学行为、评价CAR-T的激活状态具有重要意义。此外,分子影像还可对CAR-T治疗效果及可能产生的相关不良反应进行早期预测,从而为临床干预提供有效信息,并在指导CAR-T疗法研发中起到重要作用。

Chimeric antigen receptor T-cell(CAR-T)therapy is an emerging cancer immunotherapy strategy in recent years.CAR-T therapy has shown significant efficacy in the treatment of relapsed or refractory diffuse large B cell lymphoma and refractory pediatric acute lymphoblastic leukemia.However,restricted by the complexity of solid tumor microenvironment,the application of CAR-T therapy in solid tumors is still underway.Molecular imaging can trace the in vivo status of T cells in real time and in depth,which is of great significance to investigate the biological behavior of CAR-T cells in vivo and to evaluate their activation status.Meanwhile,molecular imaging strategy can also act as an early predictor of CAR-T treatment efficacy and related side effects,which can provide effective information for clinical intervention and play an important role in guiding the development of CAR-T therapy.